
    
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the efficacy and safety of imsidolimab in adult subjects with hidradenitis
      suppurativa (HS). This study also will characterize the pharmacokinetic (PK) profile of
      imsidolimab and explore the immune response to imsidolimab in subjects with HS.
    
  